Chimeric antigen receptor targeting CD19 and application thereof
Patent Information
- Application Number
- CN202380035804.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-29
- Filing Date
- 2023-04-28
- Publication Date
- 2024-12-06
AI Technical Summary
Existing CD19 CAR-T products use the mouse-derived antibody FMC63, which leads to immunogenicity and the production of heterologous antibodies in patients, resulting in rapid clearance of CAR-T cells and disease relapse. The preparation process is complex and expensive, and there are limitations in toxic effects.
Develop chimeric antigen receptors targeting CD19, containing an antigen-binding region that specifically binds CD19, reducing immunogenicity through humanized antibodies, and combining NK cells as exemplary effector cells for the preparation of shelf-ready therapeutic products.
It achieves specific killing and inhibition of CD19-positive tumor cells, reduces immunogenicity, simplifies the preparation process, reduces toxic effects, and improves the safety and effectiveness of treatment.
Smart Images

Figure 00000023_0000 
Figure 00000023_0001 
Figure 00000025_0000
Abstract
Description
Chimeric antigen receptor targeting CD19 and its application
[0001] Citation of Related Applications
[0002] This application claims priority to Chinese Patent Application No. 202210468137.4 filed on April 29, 2022, the contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field
[0003] The present application relates generally to the fields of bioengineering and cell therapy, and more particularly to chimeric antigen receptors targeting CD19 and their applications. Background Art
[0004] CD19 is a member of the immunoglobulin superfamily. It is a 95kDa type I transmembrane glycoprotein composed of a single transmembrane domain, an N-terminal extracellular domain, and a C-terminal intracellular domain. The N-terminal extracellular domain consists of two C2-type Ig-like domains, while the C-terminal intracellular domain is highly conserved, consisting of 242 amino acids and nine tyrosine residues near the C-terminus. CD19 plays a crucial role in regulating the activation and proliferation of B lymphocytes and is widely expressed on the surface of B cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphomas (diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma (FL).
[0005] In recent years, breakthroughs have been made in cellular immunotherapy, particularly those based on chimeric antigen receptors (CARs). CD19 has become a popular target for CAR technology, and CAR-T products specifically targeting CB19 have been approved for marketing by the US FDA. However, existing CD19 CAR-T products use the murine antibody FMC63, which is immunogenic. The human body is prone to producing anti-antibodies (ADA) or cytotoxic T lymphocytes (CTLs) against the heterologous antibodies used in CAR-Ts, leading to rapid clearance of CAR-T cells and relapse in some patients.
[0006] Furthermore, although CAR-modified T cells have anti-tumor activity, they still have certain limitations in terms of overall management and clinical application. CAR T cells are prepared for individual patients, making the preparation process complex and expensive. Some patients experience significant toxic effects after receiving CAR T-cell therapy (including cytokine release syndrome and neurotoxicity, requiring treatment in specialized treatment institutions). Effective allogeneic products with a better safety profile could overcome these limitations.
[0007] SUMMARY OF THE INVENTION
[0008] In a first aspect, the present application provides a nucleic acid molecule encoding a chimeric antigen receptor targeting CD19, wherein the chimeric antigen receptor comprises: an extracellular region comprising an antigen binding region that specifically binds to CD19, a transmembrane region connected to the extracellular region, and an intracellular domain connected to the transmembrane region, wherein the antigen binding region comprises a VH comprising HCDR1-3 and a VL comprising LCDR1-3, wherein:
[0009] (1) the HCDR1-3 have the sequences shown in SEQ ID NOs: 9-11, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 12-14, respectively; or
[0010] (2) the HCDR1-3 have the sequences shown in SEQ ID NOs: 15-17, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 18-20, respectively; or
[0011] (3) the HCDR1-3 have the sequences shown in SEQ ID NOs: 21-23, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 24-26, respectively; or
[0012] (4) the HCDR1-3 have the sequences shown in SEQ ID NOs: 27-29, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 30-32, respectively; or
[0013] (5) The HCDR1-3 each have at most 0-3 mutations compared to each corresponding CDR in any one of groups (1)-(4), and the LCDR1-3 each have at most 0-3 mutations compared to each corresponding CDR in any one of groups (1)-(4).
[0014] In a second aspect, the present application provides a chimeric antigen receptor targeting CD19 encoded by the nucleic acid molecule of the first aspect.
[0015] In a third aspect, the present application provides a vector comprising the nucleic acid molecule described in the first aspect.
[0016] In a fourth aspect, the present application provides immune effector cells, wherein the immune effector cells are introduced with the nucleic acid molecule described in the first aspect or the vector described in the third aspect or express the chimeric antigen receptor described in the second aspect.
[0017] In a fifth aspect, the present application provides a method for preparing immune effector cells, which comprises: providing immune effector cells, and introducing the nucleic acid molecule described in the first aspect or the vector described in the third aspect into the immune effector cells. Optionally, the method further comprises culturing the immune effector cells after the introduction of the nucleic acid molecule or vector.
[0018] In a sixth aspect, the present application provides a product prepared according to the method described in the fifth aspect.
[0019] In the seventh aspect, the present application provides a pharmaceutical composition comprising the nucleic acid molecule described in the first aspect or the vector described in the third aspect or the immune effector cell described in the fourth aspect or the product described in the sixth aspect, and a pharmaceutically acceptable carrier.
[0020] In the eighth aspect, the present application provides the use of the nucleic acid molecule of the first aspect, the vector of the third aspect, the immune effector cell of the fourth aspect, the product of the sixth aspect, or the pharmaceutical composition of the seventh aspect in the preparation of a drug for treating a tumor or cancer, wherein the tumor or cancer is preferably a CD19-related tumor or cancer, more preferably a B-cell malignancy, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, monoclonal antibody of undetermined significance, Gammopathies, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain diseases, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt lymphoma, bilineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin lymphoma.
[0021] In the ninth aspect, the present application provides a method for treating cancer or tumors, comprising administering to a subject in need thereof an effective amount of the nucleic acid molecule of the first aspect, the vector of the third aspect, the immune effector cell of the fourth aspect, the product of the sixth aspect, or the pharmaceutical composition of the seventh aspect, wherein the tumor or cancer is preferably a CD19-related tumor or cancer, more preferably a B-cell malignancy, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, or myeloma of insignificant significance. The patient may have an unrecognized monoclonal gammopathy, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt lymphoma, bilineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin lymphoma.
[0022] BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG1 shows a schematic diagram of the structure of a chimeric antigen receptor targeting CD19.
[0024] Figure 2 shows the in vitro killing effect of different CD19 CAR NK cells on Nalm6 cells, wherein the three bars in each group show the results at effector-target ratios (E:T) of 0.5:1, 1:1, and 2:1 from left to right, and NT represents NK cells not transfected with CAR.
[0025] Figure 3 shows the in vitro cytotoxic effects of different CD19 CAR NK cells on Raji cells, wherein the three bars in each group show the results at effector-target ratios (E:T) of 0.5:1, 1:1, and 2:1 from left to right, and NT represents NK cells not transfected with CAR.
[0026] Figure 4 shows the in vitro killing effect of different CD19 CAR NK cells on Molm13 cells, wherein the three bars in each group show the results at effector-target ratios (E:T) of 0.5:1, 1:1, and 2:1 from left to right, and NT represents NK cells not transfected with CAR.
[0027] Figure 5 shows the tumor imaging results of the Nalm6 xenograft model in animals after receiving different CD19 CAR NK therapies, where the NT group corresponds to blank NK in Table 5, the Mab01-CAR1 group corresponds to Mab01-CAR in Table 5, the Mab03-CAR group corresponds to Mab03-CAR3 in Table 5, and the FMC63-CAR group corresponds to FMC63-CAR4 in Table 5.
[0028] Figure 6A shows the expansion of different CD19 CAR NK cells, where UT stands for untreated.
[0029] Figure 6B shows the CAR cell positive rate during the expansion and culture of different CD19 CAR NK cells.
[0030] Figures 7A and 7B show the killing effects of different CD19 CAR NK cells on Raji cells, wherein Figure 7A shows the results at 0 h of recovery, and Figure 7B shows the results 24 h after recovery.
[0031] Figures 8A and 8B show the tumor imaging results of the Nalm6 xenograft model in animals after receiving different CD19 CAR NK therapies, wherein Figure 8A shows the results from days 5 to 26 and Figure 8B shows the results from days 30 to 33.
[0032] Figure 8C shows the photon quantity results of Nalm6 xenograft model tumor imaging in animals after receiving different CD19 CAR NK treatments (since death occurred in the negative control group starting from day 19, the photon quantity data was only counted up to day 19).
[0033] Figure 8D shows the body weight test results of Nalm6 xenograft model animals after receiving different CD19 CAR NK treatments (since death occurred in the negative control group starting from day 19, the body weight data were only counted up to day 19).
[0034] Figure 8E shows the survival curves of Nalm6 xenograft model animals after receiving different CD19 CAR NK therapies.
[0035] Figure 9A shows the expression of CD56 in peripheral blood samples obtained from Nalm6 xenograft model animals treated with different CD19 CAR NK cells. + CAR19 + CD3 - Cell ratio.
[0036] Figure 9B shows the expression of CD56 in peripheral blood samples obtained from Nalm6 xenograft model animals treated with different CD19 CAR NK cells. + CAR19 - CD3 - Cell ratio.
[0037] FIG10 shows a summary of Nalm6 xenograft model efficacy testing for different CD19 CAR NK treatment groups.
[0038] Detailed Description of the Invention
[0039] Definitions and Explanations of Terms
[0040] Unless otherwise defined herein, scientific and technical terms related to the present application shall have the meanings understood by those of ordinary skill in the art.
[0041] Furthermore, unless otherwise indicated herein, singular terms shall include pluralities and plural terms shall include the singular. More specifically, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly indicated otherwise.
[0042] The terms "comprising," "including," and "having" are used interchangeably herein to indicate the inclusiveness of a solution, meaning that the solution may contain other elements in addition to the listed elements. It should also be understood that the use of "comprising," "including," and "having" in this document also provides for "consisting of" solutions. For example, "a composition comprising A and B" should be understood to include the following technical solutions: a composition consisting of A and B, as well as a composition containing other components in addition to A and B, all fall within the scope of the aforementioned "a composition."
[0043] The term "and / or" as used herein includes the meanings of "and," "or," and "all or any other combination of elements linked by the associated term."
[0044] Although the numerical ranges and parameter approximations shown in the broad scope of this application, the numerical values shown in the specific examples are recorded as accurately as possible. However, any numerical value is necessarily contained in a certain error, which is caused by the standard deviation present in their respective measurements. In addition, all ranges disclosed herein should be understood to cover any and all sub-ranges contained therein. For example, a range of "1 to 10" should be considered to include any and all sub-ranges between a minimum of 1 and a maximum of 10 (including endpoints); that is, all sub-ranges starting with a minimum of 1 or greater, such as 1 to 6.1, and sub-ranges ending with a maximum of 10 or less, such as 5.5 to 10. In addition, any reference referred to as "incorporated herein" should be understood to be incorporated in its entirety.
[0045] As used herein, "chimeric antigen receptor (CAR)" refers to an artificial immune effector cell surface receptor that is modified to express on immune effector cells and specifically binds to an antigen, and includes at least: (1) an extracellular antigen binding domain, such as a variable heavy chain or light chain of an antibody; (2) a transmembrane domain that anchors CAR into immune effector cells; and (3) an intracellular signaling domain. CAR can redirect T cells and other immune effector cells to selected targets, such as cancer cells, in a non-MHC restricted manner using the extracellular antigen binding domain. The extracellular domain of the chimeric antigen receptor can also include a signal peptide and / or a hinge region. The intracellular domain of the chimeric antigen receptor can also include a costimulatory domain.
[0046] As used herein, the term "signal peptide" in the context of chimeric antigen receptors refers to a segment of a protein or polypeptide that is used to guide the protein or polypeptide into the secretory pathway, translocate to the cell membrane and / or cell surface. A non-limiting example of a signal peptide is the CD8α signal peptide.
[0047] As used herein, the term "hinge region" in the context of a chimeric antigen receptor generally refers to any oligopeptide or polypeptide that acts to connect the transmembrane region and the antigen binding region. Specifically, the hinge region is used to provide greater flexibility and accessibility to the antigen binding region. The hinge region can be derived in whole or in part from natural molecules, such as in whole or in part from the extracellular region of CD8, CD4 or CD28, or in whole or in part from an antibody constant region. Alternatively, the hinge region can be a synthetic sequence corresponding to a naturally occurring hinge sequence, or can be a fully synthetic hinge sequence.
[0048] As used herein, the term "transmembrane (TM) region" in the context of a chimeric antigen receptor refers to a polypeptide structure that enables a chimeric antigen receptor to be expressed on the surface of an immune cell (e.g., a lymphocyte, NK cell, or NKT cell) and guides the immune cell to respond to a target cell. The transmembrane domain may be natural or synthetic, or may be derived from any membrane-bound protein or transmembrane protein. When the chimeric antigen receptor binds to the target antigen, the transmembrane domain is capable of signal transduction. A non-limiting example of a hinge region is the CD8 transmembrane region.
[0049] As used herein, the term "intracellular signaling domain" in the context of a chimeric antigen receptor refers to a portion of a protein that transduces effector function signals and directs cells to perform designated functions. The intracellular signaling domain is responsible for primary signaling within the cell after the antigen binding domain binds to the antigen, leading to activation of immune cells and immune responses. In other words, the intracellular signaling domain is responsible for activating at least one of the normal effector functions of the immune cell in which the CAR is expressed. Exemplary intracellular signaling domains include CD3ζ.
[0050] As used herein, the term "costimulatory domain" in the context of a chimeric antigen receptor refers to the intracellular signaling domain of a costimulatory molecule. Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors that provide a second signal required for the effective activation and function of T lymphocytes after binding to an antigen. A non-limiting example of a costimulatory domain is the CD28 costimulatory domain.
[0051] As used herein, the term "immune effector cell" or "effector cell" refers to a cell that participates in an immune response, such as a cell that promotes an immune effector response. Examples of immune effector cells include T cells, such as α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.
[0052] The term "specific binding" herein refers to the ability of an antigen-binding molecule (e.g., an antibody or a ligand of an antigen) to specifically bind to an antigen and substantially the same antigen, typically with high affinity, but not to unrelated antigens with high affinity. Affinity is typically measured as an equilibrium dissociation constant (KD), where a lower KD indicates a higher affinity. For example, for antibodies, a high affinity typically refers to a specific affinity of about 10 -6 M or lower, about 10 -7 M or lower about 10 -8 M or lower, about 1×10 -9 M or lower, about 1×10 -10 M or less, 1×10 -11M or lower or 1×10 -12 The KD is calculated as follows: KD = Kd / Ka, where Kd represents the off-rate and Ka represents the on-rate. The equilibrium dissociation constant, KD, can be measured using methods known in the art, such as surface plasmon resonance (e.g., Biacore) or equilibrium dialysis. For example, see the methods for obtaining KD values described in the Examples herein.
[0053] The term "antibody" herein is used in the broadest sense to refer to a polypeptide or combination of polypeptides that contains sufficient sequence from the variable region of an immunoglobulin heavy chain and / or sufficient sequence from the variable region of an immunoglobulin light chain to specifically bind to an antigen. "Antibodies" herein encompass various forms and structures, as long as they exhibit the desired antigen-binding activity, including intact antibodies and antigen-binding fragments thereof.
[0054] The term "antibody" herein includes a typical "four-chain antibody," which is an immunoglobulin composed of two heavy chains (HC) and two light chains (LC). The heavy chain refers to a polypeptide chain that, from the N-terminus to the C-terminus, consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain. Furthermore, when the full-length antibody is of the IgE isotype, it optionally also includes a heavy chain constant region CH4 domain. The light chain is a polypeptide chain that, from the N-terminus to the C-terminus, consists of a light chain variable region (VL) and a light chain constant region (CL). Heavy chains are linked to each other and to each other through disulfide bonds, forming a "Y"-shaped structure. Due to the different amino acid composition and arrangement order of the constant regions of the heavy chains of immunoglobulins, their antigenicity also varies. Based on this, "immunoglobulins" as used herein can be divided into five classes, or isotypes, namely IgM, IgD, IgG, IgA, and IgE. Their corresponding heavy chains are μ, δ, γ, α, and ε, respectively. Igs within the same class are further divided into subclasses based on the amino acid composition of their hinge regions and the number and location of disulfide bonds in their heavy chains. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4, and IgA can be divided into IgA1 and IgA2. Light chains are classified as either kappa or lambda chains based on differences in their constant regions. Each of the five Ig classes can have either kappa or lambda chains.
[0055] "Antigen-binding fragment" and "antibody fragment" are used interchangeably herein and do not have the entire structure of an intact antibody, but only contain a portion or partial variant of an intact antibody that has the ability to bind to an antigen. "Antigen-binding fragment" or "antibody fragment" herein includes, but is not limited to, Fab, Fab', Fab'-SH, F(ab')2, scFv, and VHH.
[0056] The term "scFv" (single-chain variable fragment) herein refers to a single polypeptide chain comprising a VL and VH domain, wherein the VL and VH are connected by a linker (see, e.g., Bird et al., Science 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Roseburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers include GSTSGSGKPGSGEGSTKG and consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol. In some cases, a disulfide bond can also exist between the VH and VL of the scFv to form a disulfide-linked Fv (dsFv).
[0057] As used herein, "antibodies" may be derived from any animal, including but not limited to humans and non-human animals, which may be selected from primates, mammals, rodents, and vertebrates, such as camelids, llamas, ostriches, alpacas, sheep, rabbits, mice, rats, or cartilaginous fish (e.g., sharks).
[0058] The term "humanized antibody" means an antibody obtained by grafting CDR sequences derived from another mammalian species, such as a mouse germline, onto human framework sequences. In order to retain binding affinity, some residues of the backbone (called FR) segment may be modified. Humanized antibodies or fragments thereof according to the present application may be prepared by techniques known to those skilled in the art.
[0059] The term "variable region" herein refers to the region of an antibody heavy or light chain that is involved in binding the antibody to an antigen. "Heavy chain variable region" is used interchangeably with "VH" and "HCVR," and "light chain variable region" is used interchangeably with "VL" and "LCVR." The variable domains of the heavy and light chains of native antibodies (VH and VL, respectively) generally have similar structures, each comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. The terms "complementarity determining region" and "CDR" are used interchangeably herein and generally refer to the hypervariable regions (HVRs) of the heavy chain variable region (VH) or light chain variable region (VL). These regions are also called complementarity determining regions because they form precise spatial complementarity with antigenic epitopes. The heavy chain variable region CDRs can be abbreviated as HCDRs, and the light chain variable region CDRs can be abbreviated as LCDRs. The terms "framework region" or "FR region" are used interchangeably and refer to the amino acid residues in the heavy chain variable region or light chain variable region of an antibody, excluding the CDRs. A typical antibody variable region is composed of four FR regions and three CDR regions in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0060] For further description of CDRs, see Kabat et al., J. Biol. Chem., 252:6609-6616 (1977); Kabat et al., U.S. Department of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273:927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45:3832-3839 (2008); Lefranc et al., J. Mol. Biol. 196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273:927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45:3832-3839 (2008); Lefranc et al., J. Mol. MP et al., Dev. Comp. Immunol., 27:55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001). "CDRs" herein can be annotated and defined by methods well known in the art, including but not limited to the Kabat numbering system, using tool websites including but not limited to the abYsis website (www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi).
[0061] The term "Kabat numbering system" herein generally refers to the immunoglobulin alignment and numbering system proposed by Elvin A. Kabat (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
[0062] As used herein, the terms "percent (%) sequence identity" and "percent (%) sequence identity" are interchangeable and refer to the percentage of amino acid (or nucleotide) residues of a candidate sequence that are identical to the amino acid (or nucleotide) residues of a reference sequence after aligning sequences and introducing gaps (if necessary) to achieve maximum percent sequence identity (e.g., for optimal alignment, gaps can be introduced into one or both of the candidate and reference sequences, and for the purpose of comparison, non-homologous sequences can be ignored). For the purpose of determining percent sequence identity, alignment can be achieved in a variety of ways well known to those skilled in the art, such as using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAIi) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm that requires achieving maximum alignment over the full length of the compared sequences. For example, a reference sequence aligned for comparison with a candidate sequence can show that the candidate sequence exhibits from 50% to 100% sequence identity over the full length of the candidate sequence or a selected portion of the continuous amino acid (or nucleotide) residues of the candidate sequence. The length of the candidate sequence aligned for comparison purposes can be, for example, at least 30% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid (or nucleotide) residue as the corresponding position in the reference sequence, then the molecules are identical at that position.
[0063] As used herein, "mutation" includes insertion mutation, deletion mutation and substitution mutation. In some embodiments, the substitution mutation is preferably a conservative amino acid substitution.
[0064] As used herein, "conservative amino acids" generally refer to amino acids that belong to the same class or have similar characteristics (e.g., charge, side chain size, hydrophobicity, hydrophilicity, main chain conformation, and rigidity). Exemplarily, the amino acids within each of the following groups are conservative amino acid residues of each other, and substitutions of amino acid residues within the group are substitutions of conservative amino acids:
[0065] Illustratively, the following six groups are examples of amino acids that are considered to be conservative substitutions for each other:
[0066] 1) Alanine (A), serine (S), threonine (T);
[0067] 2) Aspartic acid (D), glutamic acid (E);
[0068] 3) Asparagine (N), glutamine (Q);
[0069] 4) Arginine (R), Lysine (K), Histidine (H);
[0070] 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
[0071] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W).
[0072] As used herein, "at most X mutations" means that the number of mutations can be selected from any natural number in the range of 0 to X.
[0073] As used herein, "at most 0-3 mutations" can mean 3 mutations, 2 mutations, 1 mutation, or 0 mutations. As used herein, "respectively" in "the HCDRs 1-3 each have at most 0-3 mutations" means that the number of mutations in each CDR in HCDRs 1-3 is independent of each other and can be independently selected from 0-3. Similarly, as used herein, "respectively" in "the LCDRs 1-3 each have at most 0-3 mutations" means that the number of mutations in each CDR in LCDRs 1-3 is independent of each other.
[0074] As used herein, a "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the interior of a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be interpreted to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acids into cells, such as polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, and retroviral vectors.
[0075] As used herein, the terms "subject," "object," and "patient" refer to an organism that is being treated for a particular disease or condition, such as cancer or an infectious disease, as described herein. Examples of subjects and patients include mammals such as humans, primates, pigs, goats, rabbits, hamsters, cats, dogs, guinea pigs, members of the Bovidae family (such as cattle, bison, buffalo, elk, and yaks, etc.), cattle, sheep, horses, and bison, etc., that are being treated for a disease or condition, such as a cell proliferative disorder, such as cancer or an infectious disease.
[0076] As used herein, the term "treatment" refers to surgical or therapeutic treatment, the purpose of which is to prevent, slow down (reduce) undesirable physiological changes or lesions in the treated subject, such as the progression of a cell proliferative disorder (such as cancer or an infectious disease). Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, attenuation of the extent of the disease, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and relief (whether partial relief or complete relief), whether detectable or undetectable. Subjects in need of treatment include subjects already suffering from a disease or disease, as well as subjects susceptible to a disease or disease, or subjects intending to prevent a disease or disease. When referring to terms such as slowing down, alleviating, weakening, alleviating, and alleviating, their meanings also include situations such as elimination, disappearance, and non-occurrence.
[0077] As used herein, the term "effective amount" refers to an amount of a therapeutic agent that, when administered alone or in combination with another therapeutic agent to a cell, tissue, or subject, is effective in preventing or ameliorating a disease symptom or the progression of that disease. "Effective amount" also refers to an amount of a compound sufficient to alleviate symptoms, e.g., to treat, cure, prevent, or alleviate a related medical condition, or to increase the rate of treatment, cure, prevention, or alleviation of such a condition. When an active ingredient is administered alone to a subject, a therapeutically effective dose refers to that ingredient alone. When a combination is used, a therapeutically effective dose refers to the combined amounts of the active ingredients that produce a therapeutic effect, whether administered in combination, sequentially, or simultaneously.
[0078] As used herein, the term "cancer" refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Both benign and malignant cancers are included in this definition. As used herein, the terms "tumor" or "neoplasm" refer to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer" and "tumor" are not mutually exclusive when used herein.
[0079] The term "pharmaceutical composition" as used herein refers to a combination of at least one drug and optionally a pharmaceutically acceptable carrier or excipient that is combined together to achieve a specific purpose. In certain embodiments, the pharmaceutical composition includes a combination separated in time and / or space, as long as it can work together to achieve the purpose of the present application. For example, the ingredients contained in the pharmaceutical composition (such as CAR-NK cells according to the present application) can be administered to an individual as a whole, or separately. When the ingredients contained in the pharmaceutical composition are administered separately to an individual, the ingredients can be administered to the individual simultaneously or sequentially. The pharmaceutical composition according to the present application may include conventional components of cell culture to maintain the activity of CAR-NK cells. Pharmaceutically acceptable carriers may also include water, buffered aqueous solutions, isotonic saline solutions such as PBS (phosphate buffered saline), glucose, mannitol, dextrose, lactose, starch, magnesium stearate, cellulose, magnesium carbonate, 0.3% glycerol, hyaluronic acid, ethanol or polyalkylene glycols such as polypropylene glycol, triglycerides, etc. The pharmaceutical composition or pharmaceutical preparation according to the present application can be administered by any suitable route, such as intravenous administration, intradermal, subcutaneous, intramuscular injection, etc. The composition according to the present application may contain wetting agents, emulsifiers or buffer substances as additives.
[0080] After extensive research and testing, the inventors of this application have developed a new chimeric antigen receptor targeting CD19 and its application, and provide a chimeric antigen receptor targeting CD19 and corresponding nucleic acid molecules, vectors, immune effector cells, preparation methods and products thereof, pharmaceutical compositions, therapeutic uses, pharmaceutical uses, and tumor or cancer treatment methods. Each invention of this application achieves at least one of the following beneficial effects: (1) It has a specific killing effect on CD19-positive tumor cells and / or an inhibitory effect on the growth of CD19-related tumors; (2) The chimeric antigen receptor targeting CD19 is humanized to reduce immunogenicity; (3) Taking the exemplary effector cell NK cell as an example, it has the application prospect of a "shelf-type" therapeutic product.
[0081] In a first aspect, the present application provides a nucleic acid molecule encoding a chimeric antigen receptor targeting CD19, wherein the chimeric antigen receptor comprises: an extracellular region comprising an antigen binding region that specifically binds to CD19, a transmembrane region connected to the extracellular region, and an intracellular domain connected to the transmembrane region, wherein the antigen binding region comprises a VH comprising HCDR1-3 and a VL comprising LCDR1-3, wherein:
[0082] (1) the HCDR1-3 have the sequences shown in SEQ ID NOs: 9-11, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 12-14, respectively; or
[0083] (2) the HCDR1-3 have the sequences shown in SEQ ID NOs: 15-17, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 18-20, respectively; or
[0084] (3) the HCDR1-3 have the sequences shown in SEQ ID NOs: 21-23, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 24-26, respectively; or
[0085] (4) the HCDR1-3 have the sequences shown in SEQ ID NOs: 27-29, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 30-32, respectively; or
[0086] (5) The HCDR1-3 have at most 0-3 mutations (e.g., 0, 1, 2, 3 mutations) compared to each corresponding CDR in any one of groups (1)-(4), and the LCDR1-3 have at most 0-3 mutations (e.g., 0, 1, 2, 3 mutations) compared to each corresponding CDR in any one of groups (1)-(4).
[0087] In some embodiments, (1) the VH has the sequence shown in SEQ ID NO: 1, and the VL has the sequence shown in SEQ ID NO: 2; or (2) the VH has the sequence shown in SEQ ID NO: 40, and the VL has the sequence shown in SEQ ID NO: 39; or (3) the VH has the sequence shown in SEQ ID NO: 41, and the VL has the sequence shown in SEQ ID NO: 38; or (4) the VH has the sequence shown in SEQ ID NO: 3, and the VL has the sequence shown in SEQ ID NO: 4; (5) the VH has the sequence shown in SEQ ID NO: 5, and the VL has the sequence shown in SEQ ID NO: 6; (6) the VH has the sequence shown in SEQ ID NO: 7 or 43, and the VL has the sequence shown in SEQ ID NO: 44. NO:8 or 42; or (7) the VH has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%) or at most 25 mutations (e.g., at most 20 mutations, at most 15 mutations, at most 10 mutations, at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations) compared to the corresponding VH of any of groups (1) to (6). mutations or 1 mutation), said VL having at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%) or a sequence of at most 20 mutations (e.g., at most 15 mutations, at most 10 mutations, at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations or 1 mutation) with the corresponding VL of any of groups (1)-(6).
[0088] In some embodiments, the antigen binding region is in the form of a scFv.
[0089] In some embodiments, the antigen binding region in scFv format has:
[0090] (1) the amino acid sequence shown in SEQ ID NO: 51, 55 or 56; or
[0091] (2) the amino acid sequence shown in SEQ ID NO: 52; or
[0092] (3) the amino acid sequence shown in SEQ ID NO: 53; or
[0093] (4) the amino acid sequence shown in SEQ ID NO: 54 or 57; or
[0094] (5) an amino acid sequence having at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) or at most 50 mutations (e.g., at most 45 mutations, at most 40 mutations, at most 35 mutations, at most 30 mutations, at most 25 mutations, at most 20 mutations, at most 15 mutations, at most 10 mutations, at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation) to the amino acid sequence of any one of SEQ ID NOs: 51-57.
[0095] In some embodiments, the chimeric antigen receptor comprises a CD8α signal peptide, an antigen binding region that specifically binds to CD19, a CD8 hinge region, a CD8 transmembrane region, a CD28 costimulatory domain, and CD3ζ.
[0096] In some embodiments, the CD8α signal peptide has the amino acid sequence of SEQ ID NO: 33 or has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) to the amino acid sequence of SEQ ID NO: 33, or at most 10 mutations (e.g., at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation).
[0097] In some embodiments, the CD8α hinge region has the amino acid sequence of SEQ ID NO: 47 or has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) to the amino acid sequence of SEQ ID NO: 47, or at most 10 mutations (e.g., at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation).
[0098] In some embodiments, the CD8 transmembrane region has the amino acid sequence of SEQ ID NO: 48 or has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%) to the amino acid sequence of SEQ ID NO: 48 or at most 10 mutations (e.g., at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations or 1 mutation).
[0099] In some embodiments, the CD3ζ has the amino acid sequence of SEQ ID NO: 49, or has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) to the amino acid sequence of SEQ ID NO: 49, or at most 10 mutations (e.g., at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation).
[0100] In some embodiments, the CD28 costimulatory domain has the amino acid sequence of SEQ ID NO:50, or has at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) to the amino acid sequence of SEQ ID NO:50, or at most 10 mutations (e.g., at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation).
[0101] In some embodiments, the chimeric antigen receptor further comprises a cytokine linked by a self-cleaving peptide. In some embodiments, the cytokine is IL15. In some embodiments, the self-cleaving peptide is selected from F2A, T2A, P2A, and E2A.
[0102] In some embodiments, the chimeric antigen receptor has a sequence as shown in any one of SEQ ID NOs: 34-37 or 44-46, or has a sequence as shown in any one of SEQ ID NOs: 34-37 or 44-46. or a sequence having at least 80% identity (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) or at most 120 amino acid mutations (e.g., at most 110 mutations, at most 100 mutations, at most 90 mutations, at most 80 mutations, at most 70 mutations, at most 60 mutations, at most 50 mutations, at most 45 mutations, at most 40 mutations, at most 35 mutations, at most 30 mutations, at most 25 mutations, at most 20 mutations, at most 15 mutations, at most 10 mutations, at most 5 mutations, at most 4 mutations, at most 3 mutations, at most 2 mutations, or 1 mutation) compared to any of NOs: 34-37 or 44-46.
[0103] In some embodiments, the nucleic acid molecule is DNA or RNA.
[0104] In some embodiments, the RNA is mRNA.
[0105] In some embodiments, the nucleic acid molecule is an isolated nucleic acid molecule. In some embodiments, the nucleic acid molecule is operably linked to a regulatory sequence that can be recognized by a host cell transformed with the vector.
[0106] In a second aspect, the present application provides a chimeric antigen receptor targeting CD19 encoded by the nucleic acid molecule of the first aspect.
[0107] In a third aspect, the present application provides a vector (eg, an expression vector) comprising the nucleic acid molecule of the first aspect.
[0108] In a fourth aspect, the present application provides immune effector cells, wherein the immune effector cells are introduced with the nucleic acid molecule described in the first aspect or the vector described in the third aspect or express the chimeric antigen receptor described in the second aspect.
[0109] In some embodiments, the immune effector cells are NK cells, T cells, or NKT cells. In some embodiments, the immune effector cells are NK cells. In some embodiments, the NK cells are differentiated from iPSCs, or derived from peripheral blood or umbilical cord blood.
[0110] There are various techniques for culturing, expanding and obtaining NK cells in vitro, and the general principles and methodologies thereof are known to those skilled in the art.
[0111] In some embodiments, NK cells are obtained from the in vitro culture and expansion of NK cells derived from peripheral blood mononuclear cells (PBMCs). PBMCs are one of the main sources of NK cells and have the advantages of being relatively easy to collect, easy to expand in vitro, and having no toxic side effects. However, the proportion of NK cells in PBMCs is generally 10%-15%. Methods for expanding NK cells derived from PBMCs include using a combination of cytokines, feeder cells, or membrane particles to stimulate the in vitro expansion of NK cells.
[0112] In some embodiments, NK cells are obtained from the in vitro culture and expansion of NK cells derived from umbilical cord blood. There are generally two different methods for obtaining large numbers of NK cells from umbilical cord blood. One method is to expand NK cells in umbilical cord blood, and the other method is to induce umbilical cord blood CD34+ hematopoietic stem / progenitor cells to differentiate into NK cells and then expand them.
[0113] In some embodiments, the NK cells are obtained from in vitro culture and expansion of an NK cell line. As an example, NK-92 is the first NK cell-based immunotherapy approved by the FDA for clinical trials and is a homogenous immortalized NK lymphoma cell.
[0114] In some embodiments, NK cells are obtained from the in vitro induction, culture, and expansion of induced pluripotent stem cells (iPSCs) or mesenchymal stem cells (ESCs).
[0115] In a fifth aspect, the present application provides a method for preparing immune effector cells, the method comprising: providing immune effector cells, and introducing the nucleic acid molecule described in the first aspect or the vector described in the third aspect into the immune effector cells. In some embodiments, the method further comprises culturing the immune effector cells after the introduction of the nucleic acid molecule or vector.
[0116] In a sixth aspect, the present application provides a product prepared according to the method described in the fifth aspect.
[0117] In the seventh aspect, the present application provides a pharmaceutical composition comprising the nucleic acid molecule described in the first aspect or the vector described in the third aspect or the immune effector cell described in the fourth aspect or the product described in the sixth aspect, and a pharmaceutically acceptable carrier.
[0118] In some embodiments, the pharmaceutical composition is used to treat a tumor or cancer. In some embodiments, the tumor or cancer is a CD19-associated tumor or cancer. In some embodiments, the tumor or cancer is a B-cell malignancy. In some embodiments, the tumor or cancer is acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin's lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt's lymphoma, bi-lineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin's lymphoma.
[0119] In some embodiments, a CD19-related tumor or cancer refers to tumor cells or cancer cells that express CD19 on their surface. In some embodiments, the tumor is a tumor that highly expresses CD19 (CD19+). In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 60% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 70% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 80% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 90% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 95% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) refers to at least 98% of tumor cells in a tumor cell population that express CD19. In some embodiments, a tumor that highly expresses CD19 (CD19+) means that at least 99% of the tumor cells in a tumor cell population express CD19.
[0120] In an eighth aspect, the present application provides use of the nucleic acid molecule of the first aspect, the vector of the third aspect, the immune effector cell of the fourth aspect, the product of the sixth aspect, or the pharmaceutical composition of the seventh aspect in the preparation of a medicament for treating a tumor or cancer. In some embodiments, the tumor or cancer is a CD19-associated tumor or cancer. In some embodiments, the tumor or cancer is a B-cell malignancy. In some embodiments, the tumor or cancer is acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin's lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt's lymphoma, bi-lineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin's lymphoma.
[0121] In a ninth aspect, the present application provides a method for treating cancer or tumors, comprising administering to a subject in need thereof an effective amount of the nucleic acid molecule of the first aspect, the vector of the third aspect, the immune effector cell of the fourth aspect, the product of the sixth aspect, or the pharmaceutical composition of the seventh aspect. In some embodiments, the tumor or cancer is a CD19-associated tumor or cancer. In some embodiments, the tumor or cancer is a B-cell malignancy. In some embodiments, the tumor or cancer is acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin's lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt's lymphoma, bi-lineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin's lymphoma.
[0122] It should be understood that the above detailed description is only for the purpose of enabling those skilled in the art to more clearly understand the content of the present application and is not intended to limit the present invention in any respect. Those skilled in the art can make various modifications and variations to the embodiments described. Example
[0123] The present application will be further described below with reference to specific examples, and the advantages and features of the present application will become clearer as the description proceeds. Where specific conditions are not specified in the examples, the experiments were performed under conventional conditions or those recommended by the manufacturer. Where the manufacturer of the reagents or instruments is not specified, all are commercially available conventional products.
[0124] The embodiments of the present application are merely exemplary and do not constitute any limitation on the scope of the present application. It should be understood by those skilled in the art that the details and forms of the technical solutions of the present application may be modified or replaced without departing from the spirit and scope of the present application, and such modifications and replacements shall fall within the scope of protection of the present application.
[0125] Materials and methods
[0126] SPR detection method
[0127] Anti-human CD19 antibodies were captured using a Protein A chip (GE Healthcare; 29-127-558). The sample and running buffer was HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20) (GE Healthcare; BR-1006-69). The flow-through pool was set to 25°C. The sample block was set to 16°C. Both were pretreated with running buffer. In each cycle, the antibody to be tested was first captured using the Protein A chip, then a single concentration of CD19 antigen protein was injected, the binding and dissociation process of the antibody and antigen protein was recorded, and finally the chip was regenerated using Glycine pH 1.5 (GE Healthcare; BR-1003-54). Binding was measured by injecting different concentrations of recombinant human CD19-His in solution for 240 seconds with a flow rate of 30 μl / min, starting from 200 nM (see detailed results for the actual concentrations tested), diluted 1:1, for a total of 5 concentrations. The dissociation phase was monitored for up to 600 seconds and triggered by switching from the sample solution to the running buffer. The surface was regenerated by washing with a 10 mM glycine solution (pH 1.5) at a flow rate of 30 μl / min for 30 seconds. Bulk refractive index differences were corrected by subtracting the response obtained from the goat anti-human Fc surface. Blank injections (= double reference) were also subtracted. The apparent KD and other kinetic parameters were calculated using the Langmuir 1:1 model.
[0128] Virus packaging
[0129] The day before virus packaging, trypsinize 293T cells (purchased from ATCC) and seed them into 10 cm culture dishes at a density of 1E7 cells per dish. When transfecting cells, mix the packaging plasmid and the target plasmid and add them to α-MEM medium. In another centrifuge tube containing α-MEM medium, add HD transfection reagent (Promega, E2311). Add the diluted transfection reagent dropwise to the diluted plasmid, mix well, and let it stand at room temperature for 15 minutes. Finally, add the mixture of plasmid and transfection reagent to a 10cm culture dish, shake gently 10 times, mix well, and place it in the incubator. 3 days after cell transfection, harvest the virus and transfer 10ml of the virus-containing culture supernatant to a 50ml centrifuge tube. Incubate at 4°C, 1250rpm, for 5 minutes to remove dead 293T cells. Filter the virus-containing supernatant and concentrate it using Retro-X Concentrator (Clontech, 631455). Aliquot and store at -80°C until use.
[0130] NK cell purification and activation
[0131] NK cells are isolated from monocytes and the purification process is divided into two steps. The first step is to remove CD3 + Cells, second step enrichment of CD56 + Cells were washed, incubated with CD3 magnetic beads, and resuspended using Sepax, and then CD3 was removed using CliniMACS. + cells. Sepax was used to + CD3 after cell depletion - The cell product was washed, incubated with CD56 magnetic beads, and resuspended, and then CD56 was enriched using CliniMACS. + The enriched CD56 + The cells were washed and replaced with complete medium, K562 feeder cells were added, and the cells were transferred to a 37°C incubator for 5 days of activation.
[0132] Viral transduction
[0133] On day 1, add 500 μl / well of RetroNectin reagent to a 24-well plate and coat overnight at 4°C. On day 2, discard the upper layer of RetroNectin and wash with PBS, then add the packaged retrovirus and centrifuge at 2000g at 4-8°C for 60 minutes. Discard the upper viral liquid. Add 5-day activated NK cells to a 24-well plate at 3E5 / well, centrifuge at 400g for 5 minutes at room temperature, and culture in a 37°C incubator (37°C, 5% CO2). On day 3, transfer the NK cells to a 6-well plate that has not been treated with tissue culture and continue to culture. On day 6, test CAR expression to ensure that the CAR positivity rate of NK cells used for in vitro killing or in vivo killing is within the range of 60 to 80%.
[0134] Determination of tumor cell killing rate in vitro
[0135] Unless otherwise specified, the target cells referred to in the following examples were stably transfected with the luciferase gene and expressed luciferase. Fluorescence intensity was measured using a luciferase reporter assay, reflecting cell viability and NK cell cytotoxicity. The killing rate in the test wells was calculated as follows: Killing rate = (target cell well reading - test well reading) / target cell well reading × 100%.
[0136] Example 1 Preparation of CD19 Antibody
[0137] Mice were immunized with human CD19 protein (NCBI: NP_001761.3) as an immunogen. Mice with high serum antibody titers and titers approaching a plateau were selected, and their spleen cells were taken and fused with myeloma SP2 / 0 cells. After culture and screening, positive monoclonal hybridoma cells were obtained. The antibodies secreted by the positive monoclonal hybridoma cells were identified, and positive monoclonal hybridomas Mab01, Mab02, and Mab03 capable of secreting CD19 antibodies were obtained. RNA was extracted from the positive monoclonal hybridoma cells, reverse transcribed into cDNA, and the sequences of the heavy and light chain variable regions of the hybridoma positive clone antibodies were obtained by sequencing. The variable region sequences and their CDR (Kabat numbering system) sequence information are shown in Tables 1 and 2.
[0138] The heavy and light chain variable regions of Mab01, Mab02, Mab03, and the positive control FMC63 were cloned into expression vectors containing a signal peptide and a human IgG1 heavy chain constant region, and into expression vectors containing a signal peptide and a human IgG1 light chain constant region, respectively. Human-mouse chimeric antibodies were expressed, and their binding to human CD19 protein was tested by SPR (Biacore). The SPR test results are shown in Table 3, indicating that Mab01-Mab03 all exhibited good affinity for human CD19 protein.
[0139] Table 1 Antibody sequence information
[0140] Table 2 Antibody CDRs
[0141] Table 3. Affinity of chimeric antibodies to human CD19 detected by SPR (Biacore)
[0142] Example 2 Screening of chimeric antigen receptors targeting CD19
[0143] Using the anti-CD19 antibodies screened in Example 1 and the positive control FMC63 antibody, a chimeric antigen receptor targeting CD19 was constructed as shown in Figure 1. Specifically, the chimeric antigen receptor targeting CD19 includes, in sequence, a CD8α signal peptide (SP), an anti-CD19 scFv, a CD8 hinge region, a CD8 transmembrane region, a CD28 costimulatory domain, and CD3ζ, as well as IL15 connected by a self-cleaving peptide P2A. The specific sequence is detailed in Table 4. The nucleic acid molecule encoding the chimeric antigen receptor was cloned into a retroviral vector, packaged, and used to transfect NK cells.
[0144] On the sixth day after retroviral infection of NK cells, the specific killing of CD19-CAR NK cells against CD19-expressing target cells Nalm6 and Raji, as well as the nonspecific killing of target cells Molm13 that do not express CD19, was detected. CAR NK-CD19 cells: target cells (efficacy-target ratio) were set at three gradients of 0.5:1, 1:1, and 2:1. Target cells were seeded at 1E4 / well in a white opaque 96-well plate, and NK cells were added according to the efficacy-target ratio. The plates were cultured in a 37°C, 5% CO2 incubator for 4 hours. 30 μl of FIREFLYGLO luciferase reporter gene detection reagent (Meilun Bio, MA0519-1) was added. After incubation at room temperature in the dark for 10 minutes, the cells were measured using a microplate reader and the killing rate was calculated. The test results are shown in Figures 2 to 4. The results showed that FMC63-CAR, Mab01-CAR and Mab03-CAR all had strong specific killing effects on CD19-positive cells (Nalm6 and Raji cells), and there was no significant difference in the killing effects; while for CD19-negative cells, FMC63-CAR, Mab01-CAR, Mab02-CAR and Mab03-CAR did not show nonspecific killing.
[0145] The tumor inhibitory effects of Mab01-CAR and Mab03-CAR were further compared using a mouse tumor model. Specifically, NSG mice were weighed and randomly divided according to Table 5, and human acute lymphoblastic leukemia cells Nalm6 (carrying the luciferase gene) were inoculated at a cell volume of 0.25E6. A single dose of CD19 CAR NK cells (3E6 CAR-NK cells / mouse) was intravenously injected to observe the inhibitory effect on the proliferation of mouse tumor cells. The results are shown in Figure 5: Compared with NT (NK cells not transfected with CD19-CAR), Mab01-CAR, Mab03-CAR and FMC63-CAR all showed tumor inhibitory effects, among which Mab01-CAR had a stronger tumor inhibitory effect, which was significantly better than Mab03-CAR and FMC63-CAR. Mab01-CAR was selected for the next step of development.
[0146] Table 4. CD19 chimeric antigen receptor sequence information
[0147] Table 5. Grouping of NSG mice
[0148] Example 3 Humanization of murine monoclonal antibody Mab01
[0149] To reduce the immunogenicity of Mab01-CAR, Mab01 was humanized. Specifically, the IMGT (http: / / imgt.cines.fr) human antibody heavy and light chain variable region germline gene database was compared to select the heavy chain variable region germline genes IGHV1-3*01 and IGHJ6*01, and the light chain variable region germline genes IGKV6-21*01 / IGKV3-11*01 and IGKJ2*01, which are highly homologous to the murine antibody Mab01, as templates. The CDRs of the murine antibody were transplanted into the corresponding humanized templates, resulting in a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. As needed, key amino acids in the framework sequence were backmutated to their mouse counterparts to maintain the original affinity. If the antibody contained sites susceptible to chemical modification, these sites were mutated to eliminate the risk of modification. The amino acid residues in the antibody CDRs are determined using the Kabat numbering system. The sequence information of humanized VH and VL is shown in Table 6, and the resulting humanized antibody variable region combinations are shown in Table 7.
[0150] The heavy chain variable region and light chain variable region of Hab01-4 and Hab01-11 were cloned into an expression vector containing a signal peptide and a mouse IgG1 heavy chain constant region and an expression vector containing a signal peptide and a mouse IgG1 light chain constant region, respectively. Humanized antibodies with variable regions were expressed, and the binding ability of the chimeric antibodies to the human CD19 protein was detected by SPR (Biacore). As shown in Table 8, both Hab01-4 and Hab01-11 had strong binding ability to the human CD19 protein.
[0151] Using the same approach, humanized FMC63 was designed and expressed, and the humanized antibody hFMC63 was constructed and expressed. The binding ability of the antibody to human CD19 protein was tested by SPR (Biacore). For detailed information, see Tables 6 and 9. hFMC63 exhibited strong binding to human CD19.
[0152] Table 6. Sequence information of humanized antibodies Mab01 and FMC63
[0153] Table 7. Variable region combinations of Mab01 humanized antibody
[0154] Table 8. Affinity of Mab01 humanized antibody to human CD19 detected by SPR (Biacore)
[0155] Table 9. Affinity of FMC63 humanized antibody to human CD19 detected by SPR (Biacore)
[0156] Example 4 Screening of humanized chimeric antigen receptors targeting CD19
[0157] The humanized antibodies Hab01-4, Hab01-11, and hFMC 63 prepared in Example 3 were loaded into the chimeric antigen receptor shown in Figure 1 to construct a humanized chimeric antigen receptor targeting CD19 (see Table 10 for specific sequence information), and the nucleic acid molecules of the numbered chimeric antigen receptors were cloned into retroviral vectors, packaged by viruses, and transfected into umbilical cord blood-derived NK cells. The expansion of NK cells and the CAR positive rate after transfection were detected, and the results are shown in Figures 6A-6B. As shown in Figure 6A, the NK cells transfected with different CAR structures were basically equivalent in expansion capacity; as shown in Figure 6B, the CAR positive rate of Hab01-4-CAR and Hab01-11-CAR was the highest, hFMC63-CAR was slightly worse, and FMC63-CAR had the lowest positive rate, but all were around 60 to 80%, which met the requirements. On the 6th day after retroviral infection of NK cells, sufficient cells were collected and frozen.
[0158] Before testing the target cell cytotoxicity, cryopreserved CAR-NK cells were revived, and the same number of CD19-CAR NK cells were mixed with target cells Raji at the time of resuscitation (0 h) and 24 h after resuscitation. The in vitro cytotoxicity of NK cells against target cells at different effector-target ratios was tested (Raji: 1E6 cells / mL). The results are shown in Figures 7A-7B. FMC63-CAR, hFMC63-CAR, Hab01-4-CAR, and Hab01-11-CAR all had a strong cytotoxic effect on Raji cells just after resuscitation (Figure 7A) and 24 h after resuscitation (Figure 7B). In comparison, the cytotoxicity of CAR-NK cells was better after 24 h of resuscitation.
[0159] A Nalm6 xenograft mouse model was constructed to evaluate the tumor inhibitory effects of FMC63-CAR, hFMC63-CAR, Hab01-4-CAR, and Hab01-11-CAR. Specifically, NOG mice were taken, weighed, and randomly divided into groups (see Table 11 for the grouping scheme). Human acute lymphoblastic leukemia Nalm6 (carrying the luciferase gene) was injected at a dose of 2.5E6 cells / mouse. Two days later, a single dose of CD19 CAR NK cells (4E6 CAR-NK cells / mouse) was intravenously injected. The time point of CD19 CAR NK cell injection was defined as day 0. Tumor development (fluorescence imaging), mouse weight, and survival status in mice in groups G1, G3, G4, G6, G8, and G10 were continuously observed. Peripheral blood was collected from mice in groups G2, G5, G7, G9, and G11 on days 0, 7, 16, and 21 for detection of CAR19. + CD56 + and CAR19 - CD56 + Peripheral blood was collected on days 0, 7, 14, and 28 for testing of routine blood tests and blood biochemical indices. The results are shown in Figures 8A to 8E, 9A to 9B, and 10.
[0160] As shown in Figures 8A to 8E, the tumor signal in the negative control group (G1 and G3 groups) continued to increase after tumor loading, and the four CD19CAR NK treatment groups (G4, G6, G8, and G10) all showed significant anti-tumor efficacy and significantly prolonged the survival of mice. Among the four CD19 CAR NK treatment groups, the Hab01-4-CAR NK treatment group (G8 group) had the best therapeutic effect. Although the G8 group, like the other treatment groups, had tumor metastasis to the head and face on day 26, it was found that the G8 group had no recurrence in other parts of the body through dorsal imaging and ventral imaging observations during the 30-33 days, while the other treatment groups also had recurrence in other parts of the body except the head and face. At the same time, from the survival curve, the survival rate of mice in the G8 group was 80% (day 36), which was better than that of other treatment groups. In terms of weight changes, mice in the four CD19 CAR-NK treatment groups were in good condition before day 19 and did not experience treatment-related toxicity such as weight loss. On day 19, they began to lose weight, and fluorescence signals were detected at the mandible. The weight loss of mice was caused by tumor recurrence. As shown in Figures 9A and 9B, in the CD19 CAR + CD56 + In terms of proportion, G5 group>G9 group>G11 group>G7 group, in CD19 CAR - CD56 + In terms of proportion, G11 group < G9 group = G7 group < G5 group. Among the G5, G7, G9 and G11 groups using humanized antibodies, G9 group CAR + The relative number of NK cells in peripheral blood mononuclear cells is higher. For details of blood routine and biochemical indicators, see Figure 10. In the G9 group, the levels of alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were lower than those in other CD19 CAR NK treatment groups, indicating a safer overall outcome.
[0161] Table 10. Sequence information of humanized chimeric antigen receptor targeting CD19
[0162] Table 11. Grouping of NOG mice
[0163] The teachings of all patents, published applications, and references cited herein are incorporated by reference in their entirety.
[0164] While example embodiments have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the embodiments as encompassed by the appended claims.
Claims
1. A nucleic acid molecule encoding a chimeric antigen receptor targeting CD19, the chimeric antigen receptor comprising: An extracellular region comprising an antigen binding region that specifically binds to CD19, a transmembrane region connected to the extracellular region, and an intracellular domain connected to the transmembrane region, wherein the antigen binding region comprises a VH comprising HCDR1-3 and a VL comprising LCDR1-3, wherein: (1) the HCDR1-3 have the sequences shown in SEQ ID NOs: 9-11, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 12-14, respectively; or (2) the HCDR1-3 have the sequences shown in SEQ ID NOs: 15-17, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 18-20, respectively; or (3) the HCDR1-3 have the sequences shown in SEQ ID NOs: 21-23, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 24-26, respectively; or (4) the HCDR1-3 have the sequences shown in SEQ ID NOs: 27-29, respectively, and the LCDR1-3 have the sequences shown in SEQ ID NOs: 30-32, respectively; or (5) The HCDR1-3 have 0-3 mutations compared with each corresponding CDR in any one of groups (1)-(4), and the LCDR1-3 have 0-3 mutations compared with each corresponding CDR in any one of groups (1)-(4).
2. The nucleic acid molecule according to claim 1, wherein: (1) the VH has the sequence shown in SEQ ID NO: 1, and the VL has the sequence shown in SEQ ID NO: 2; or (2) the VH has the sequence shown in SEQ ID NO: 40, and the VL has the sequence shown in SEQ ID NO: 39; or (3) the VH has the sequence shown in SEQ ID NO: 41, and the VL has the sequence shown in SEQ ID NO: 38; or (4) the VH has the sequence shown in SEQ ID NO: 3, and the VL has the sequence shown in SEQ ID NO: 4; (5) the VH has the sequence shown in SEQ ID NO: 5, and the VL has the sequence shown in SEQ ID NO: 6; (6) the VH has the sequence shown in SEQ ID NO: 7 or 43, and the VL has the sequence shown in SEQ ID NO: 8 or 42; or (7) The VH has a sequence that is at least 80% identical or has at most 25 mutations compared to the corresponding VH of any group in groups (1) to (6), and the VL has a sequence that is at least 80% identical or has at most 20 mutations compared to the corresponding VL of any group in groups (1) to (6).
3. The nucleic acid molecule according to any one of claims 1 to 2, wherein the antigen binding region is in the form of an scFv having: (1) the amino acid sequence shown in SEQ ID NO: 51, 55 or 56; or (2) the amino acid sequence shown in SEQ ID NO: 52; or (3) the amino acid sequence shown in SEQ ID NO: 53; or (4) the amino acid sequence shown in SEQ ID NO: 54 or 57; or (5) An amino acid sequence having at least 80% identity or at most 50 mutations compared to the amino acid sequence shown in any one of SEQ ID NOs: 51-57.
4. The nucleic acid molecule according to any one of claims 1 to 3, wherein the chimeric antigen receptor comprises a CD8α signal peptide, an antigen binding region that specifically binds to CD19, a CD8 hinge region, a CD8 transmembrane region, a CD28 costimulatory domain, and CD3ζ; preferably, The CD8α signal peptide has the amino acid sequence shown in SEQ ID NO: 33 or has at least 80% identity or at most 10 mutations to the amino acid sequence shown in SEQ ID NO: 33, and / or The CD8α hinge region has the amino acid sequence shown in SEQ ID NO: 47 or has at least 80% identity or at most 10 mutations to the amino acid sequence shown in SEQ ID NO: 47, and / or The CD8 transmembrane region has an amino acid sequence as shown in SEQ ID NO: 48 or a sequence similar to the amino acid sequence as shown in SEQ ID NO:
48. The sequences have at least 80% identity or at most 10 mutations, and / or The CD3ζ has the amino acid sequence shown in SEQ ID NO: 49 or has at least 80% identity or at most 10 mutations to the amino acid sequence shown in SEQ ID NO: 49, and / or The CD28 costimulatory domain has the amino acid sequence shown in SEQ ID NO: 50 or has at least 80% identity or up to 10 mutations to the amino acid sequence shown in SEQ ID NO:
50.
5. The nucleic acid molecule according to any one of claims 1 to 4, wherein the chimeric antigen receptor further comprises a cytokine linked by a self-cleaving peptide, optionally, the cytokine is IL15 and / or the self-cleaving peptide is selected from F2A, T2A, P2A and E2A.
6. The nucleic acid molecule according to any one of claims 1 to 5, wherein the chimeric antigen receptor has a sequence as shown in any one of SEQ ID NOs: 34 to 37 or 44 to 46, or a sequence having at least 80% identity or up to 120 amino acid mutations compared to any one of SEQ ID NOs: 34 to 37 or 44 to 46.
7. The nucleic acid molecule according to any one of claims 1 to 6, wherein the nucleic acid molecule is DNA or RNA, preferably, the RNA is mRNA.
8. A chimeric antigen receptor targeting CD19 encoded by the nucleic acid molecule according to any one of claims 1 to 7.
9. A vector comprising the nucleic acid molecule according to any one of claims 1 to 7.
10. Immune effector cells, wherein the immune effector cells are introduced with the nucleic acid molecule according to any one of claims 1 to 7 or the vector according to claim 9 or express the chimeric antigen receptor according to claim 8. The immune effector cell according to claim 10 , wherein the immune effector cell is a NK cell, a T cell or a NKT cell, preferably a NK cell.
12. The immune effector cell according to claim 11, wherein the NK cell is differentiated from iPSC, or derived from peripheral blood or umbilical cord blood.
13. A method for preparing the immune effector cell according to any one of claims 10 to 12, comprising: The method further comprises providing immune effector cells and introducing the nucleic acid molecule according to any one of claims 1 to 7 or the vector according to claim 9 into the immune effector cells. Optionally, the method further comprises culturing the immune effector cells after the nucleic acid molecule or vector is introduced.
14. The product prepared according to the method of claim 13.
15. A pharmaceutical composition comprising the nucleic acid molecule according to any one of claims 1 to 7, the vector according to claim 9, the immune effector cell according to any one of claims 10 to 12 or the product according to claim 14, and a pharmaceutically acceptable carrier.
16. The pharmaceutical composition according to claim 15, which is used to treat tumors or cancers, wherein the tumors or cancers are preferably CD19-related tumors or cancers, more preferably B-cell malignancies, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia (lymphoplasmacytic leukemia), lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt lymphoma, bi-lineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin lymphoma.
17. Use of the nucleic acid molecule according to any one of claims 1 to 7, the vector according to claim 9, the immune effector cell according to any one of claims 10 to 12, the product according to claim 14 or the pharmaceutical composition according to claim 15 in the preparation of a medicament for treating a tumor or cancer, wherein the tumor or cancer is preferably a CD19-related tumor or cancer, more preferably a B-cell malignancy, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasmacytoma, Unknown monoclonal gammopathy, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt lymphoma, bilineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin lymphoma.
18. A method for treating cancer or tumors, comprising administering to a subject in need thereof an effective amount of the nucleic acid molecule according to any one of claims 1 to 7, the vector according to claim 9, the immune effector cell according to any one of claims 10 to 12, the product according to claim 14, or the pharmaceutical composition according to claim 15, wherein the tumor or cancer is preferably a CD19-related tumor or cancer, more preferably a B-cell malignancy, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, plasma cell carcinoma, or the like. Cytoma, monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), heavy chain disease, primary amyloidosis, post-transplant lymphoproliferative disorder, Hodgkin lymphoma, MALT lymphoma, B-cell lymphoma, mantle cell lymphoma, (germinal center-like) diffuse large cell lymphoma, Burkitt lymphoma, bilineage leukemia, biphenotypic leukemia, hairy cell leukemia, precursor B acute lymphoblastic leukemia / lymphoma, primary cutaneous follicle center lymphoma, follicular lymphoma, or marginal zone B-cell non-Hodgkin lymphoma.
